Pro Medicus Limited (ASX:PME) develops and licenses medical imaging software used by hospitals and diagnostic imaging providers, with its Visage platform supporting the viewing, sharing and reporting of radiology images. The company has also been extending its technology into cardiology, digital pathology and AI-enabled reporting. Its FY26 result combined strong Revenue and Earnings growth with at least A$407 million of new contract wins, while maintaining an underlying EBIT Margin close to 75 per cent.

FY26 Revenue and Earnings Continue to Expand

For the year ended 30 June 2026, Pro Medicus reported revenue of A$261.7 million, an increase of 22.9 per cent. On a constant-currency basis, revenue was A$273.5 million, up 28.4 per cent, showing that currency movements reduced the reported growth rate. Underlying EBIT increased 24.4 per cent to A$196.1 million, while the underlying EBIT margin was 74.9 per cent.

Underlying net profit after tax rose 24.1 per cent to A$144.7 million, while constant-currency underlying NPAT increased 32.5 per cent to A$154.5 million. Reported NPAT was A$265.3 million, but because the supplied article does not provide verified detail explaining the full difference between reported and underlying earnings, the underlying figure is the more useful measure for assessing recurring operating performance.

New Contracts Add to the Revenue Pipeline

Pro Medicus signed ten new contracts during FY26 with a minimum total value of A$407 million. These included a A$170 million, ten-year agreement with UC Health in Colorado and a A$90 million, seven-year agreement with Beth Israel Lahey Health.

The company also renewed six contracts with existing customers, with those agreements worth A$141 million over five-year terms. The combination of new wins and renewals increases contracted revenue visibility, although the timing of revenue recognition depends on implementation schedules and customer transaction volumes.

Because many of Pro Medicus' agreements are long term and usage-based, growth depends not only on the headline value of new contracts but also on how quickly systems are deployed and how imaging volumes develop once customers are live.

Implementation Activity Remains an Important Growth Driver

Management said Pro Medicus completed 16 implementations during FY26. The Trinity Health implementation was described as largely complete, positioning that contract to make a fuller contribution in FY27.

Implementation timing is important because contract value does not translate immediately into reported revenue. Large hospital networks can require phased deployment, integration and testing before full transaction volumes begin to flow through the platform.

For Pro Medicus Limited (ASX:PME), the pace at which newly signed customers move from contract award to full production will therefore be one of the main drivers of FY27 revenue growth.

Margins Remain High Despite Continued Expansion

The underlying EBIT margin of 74.9 per cent remained a defining feature of the FY26 result. This level of profitability reflects the software-based nature of the business, where incremental transaction growth can be added without a proportionate increase in operating costs once systems are deployed.

Management also indicated that constant-currency EBIT and NPAT growth exceeded its 30 per cent targets. The distinction between reported and constant-currency performance is relevant because the group earns a large share of revenue in US dollars while reporting in Australian dollars.

The ability to maintain margins near current levels while adding new customers will remain an important measure of operating performance, particularly as the company broadens into adjacent imaging and reporting applications.

Balance Sheet Remains Debt-Free

Cash and financial Assets increased 19.7 per cent to A$252.3 million at the end of FY26, while the company reported no debt.

The absence of borrowings gives Pro Medicus substantial financial flexibility and means interest costs do not materially reduce operating cash generation. It also provides capacity to fund product development, implementations and broader expansion without relying on external Debt financing.

A larger cash position may become increasingly relevant as the company scales globally and invests in product development across radiology, cardiology, pathology and AI-enabled workflows.

Dividend Growth Tracks Higher Earnings

Pro Medicus declared a fully franked final Dividend of 37 cents per share, taking the total FY26 dividend to 69 cents per share. This represented an increase of 25.5 per cent from the prior year.

The higher distribution was supported by earnings growth and the company's debt-free balance sheet. At the same time, the Business continues to retain substantial cash, meaning dividend growth has not prevented the company from preserving funding capacity for operations and expansion.

Future distributions will continue to depend on earnings, cash generation and Capital requirements as implementation activity and product development continue.

Customer Concentration Remains a Key Risk

A relatively small number of large United States healthcare systems account for a meaningful share of Pro Medicus' revenue. This concentration increases the importance of contract renewals, implementation execution and customer retention.

If a large customer delays a rollout, renegotiates terms or does not renew, the financial impact could be material because individual contracts can represent substantial long-term revenue.

The six renewals signed during FY26 provide some evidence of existing customer retention, but concentration remains a structural feature of the business.

Currency Movements Can Affect Reported Growth

Currency remains another significant variable. A large portion of Pro Medicus' revenue is generated in US dollars, meaning movements in the Australian dollar can alter reported revenue and profit even when underlying operating performance is unchanged.

The difference between reported and constant-currency revenue growth in FY26 illustrates this effect. Reported revenue increased 22.9 per cent, while constant-currency revenue growth was 28.4 per cent.

A stronger Australian dollar can therefore reduce reported growth, while a weaker Australian dollar can increase translated results.

Product Expansion Creates Additional Growth Paths

Pro Medicus has been expanding beyond its core radiology platform into cardiology, digital pathology and AI-optimised reporting.

These areas could broaden the company's addressable market and deepen relationships with large healthcare customers by extending the Visage platform into additional clinical workflows.

However, the contribution from newer products will depend on customer adoption, implementation speed and competition from established imaging and healthcare software providers.

The core radiology business remains central to group earnings, so the pace at which adjacent products become financially meaningful will be an important measure of diversification.

What to Watch in FY27

The Trinity Health rollout and the conversion of newly signed contracts into revenue will be among the main operational indicators in FY27. Further implementations should help determine how quickly the A$407 million minimum contract pipeline begins contributing to reported growth.

Margins will also remain important. The FY27 half-year result should show whether the company can maintain an EBIT margin close to the FY26 level while continuing to expand its installed base.

Further contract wins and renewals will provide evidence of whether Demand from large United States healthcare systems remains active. Adoption of cardiology, pathology and AI-related products will also show whether Pro Medicus is successfully broadening the platform beyond radiology.

For Pro Medicus Limited (ASX:PME), FY26 showed that contract growth, high margins and a debt-free Balance Sheet continue to support expansion. FY27 will test how effectively that pipeline converts into Recurring Revenue and whether the company can preserve profitability as its customer base and product range grow.